Psilocybin Behavioral Health Access and Services Act Introduced

BACK TO INSIGHTS     Articles

January 31, 2023

Assembly Bill 4911, introduced in the New Jersey Assembly on December 5, 2022, would establish the Psilocybin Behavioral Health Access and Services Act (the “Act”). The Act would authorize the regulated production and use of psilocybin for behavioral healthcare and treatment. According to the Bill, New Jersey has a high number of adults living with behavioral health conditions. Furthermore, the Bill provides that national and international studies indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of behavioral health conditions such as clinical dependence disorders, depression, anxiety disorders, and end-of-life psychological distress.

For more information, contact:
John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com
Edward Hilzenrath | 973.403.3114 | ehilzenrath@bracheichler.com
Vanessa Coleman | 973.364.5208 | vcoleman@bracheichler.com

*This is intended to provide general information, not legal advice. Please contact the authors if you need specific advice.

Related Practices:   Healthcare Law